FDA will convene adcomm for Bristol-Myers' Reblozyl in MDS; FDA grants 'orphan' tags to a trio of drugs
→ Celgene and Acceleron‘s Reblozyl (luspatercept) earned an OK from the FDA last month to treat anemia in adults who require regular transfusions, but …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
